Want to join the conversation?
$HRS 4Q15 Call: Our free cash flow results coming in about $100MM above what we are guiding on Harris stand-alone basis, due to continued tightening of capital spending and improved working capital performance, including higher accounts payable.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.